Search results
Results From The WOW.Com Content Network
Overall, our findings suggest that more people over 70 years of age should be considered for statin treatment.” — Borislava Mihaylova, DPhil “Cardiovascular disease remains a leading cause ...
Cholesterol synthesis appears to occur mostly at night, [139] so statins with short half-lives are usually taken at night to maximize their effect. Studies have shown greater LDL and total cholesterol reductions in the short-acting simvastatin taken at night rather than the morning, [ 140 ] [ 141 ] but have shown no difference in the long ...
These guidelines recommend statin therapy for adults between forty and seventy-five who have diabetes, high cholesterol levels, or an estimated 10-year atherosclerotic cardiovascular disease risk ...
Fenofibrate (sold under the brand name Tricor among others), is an oral medication of the fibrate class used to treat abnormal blood lipid levels. [3] It is less commonly used compared to statins because it treats a different type of cholesterol abnormality to statins.
The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.
Statins are one of the most commonly prescribed drugs in the UK, with millions taking them to cut their chance of a heart attack or stroke. Stopping statin treatment early ‘could reduce ...
Statin-induced rhabdomyolysis is rare, occurring in less than 0.1% of people who take statins. [66] [67] [68] Statin induced rhabdomyolysis, as with other statin associated muscle symptoms, occurs most commonly in the first year of treatment but can occur at any time during treatment. [66]
Image credits: dogswithjobs There’s a popular saying that cats rule the Internet, and research has even found that the 2 million cat videos on YouTube have been watched more than 25 billion ...